Rhythm Biosciences (ASX:RHY) said it successfully activated its first commercial blood collection network of clinics across major cities, enabling the scaling of cancer blood test, ColoSTAT's commercial testing services, according to a Wednesday Australian bourse filing.

The ColoSTAT test is a blood-based test for the detection of colorectal cancer.

4Cyte Pathology activated an initial network of 38 blood collection sites across major cities in Queensland, New South Wales, and Victoria, enabling clinician referral and patient access to ColoSTAT testing through an established clinician pathway, the filing added.

Clinicians within designated 4Cyte Pathology clinics are being onboarded to provide referrals for ColoSTAT testing, with additional collection sites planned as part of the ongoing commercial rollout, the filing added.

The company said immediate scale-up can now proceed directly with physicians and through the ColoSTAT access program using a validated commercial and logistical pathway.

The company's shares rose past 3% in recent Wednesday trade.